nodes	percent_of_prediction	percent_of_DWPC	metapath
Maprotiline—HTR2C—type 2 diabetes mellitus	0.184	0.57	CbGaD
Maprotiline—CYP1A2—type 2 diabetes mellitus	0.139	0.43	CbGaD
Maprotiline—HTR7—Bromocriptine—type 2 diabetes mellitus	0.064	0.165	CbGbCtD
Maprotiline—ORM1—Nateglinide—type 2 diabetes mellitus	0.0521	0.135	CbGbCtD
Maprotiline—HTR2C—Bromocriptine—type 2 diabetes mellitus	0.0326	0.0843	CbGbCtD
Maprotiline—HTR2A—Bromocriptine—type 2 diabetes mellitus	0.0294	0.076	CbGbCtD
Maprotiline—DRD2—Bromocriptine—type 2 diabetes mellitus	0.0271	0.07	CbGbCtD
Maprotiline—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0235	0.0606	CbGbCtD
Maprotiline—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0209	0.054	CbGbCtD
Maprotiline—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.016	0.0412	CbGbCtD
Maprotiline—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0151	0.0391	CbGbCtD
Maprotiline—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0142	0.0368	CbGbCtD
Maprotiline—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.0131	0.034	CbGbCtD
Maprotiline—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.0126	0.0325	CbGbCtD
Maprotiline—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.0119	0.0307	CbGbCtD
Maprotiline—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.0108	0.0279	CbGbCtD
Maprotiline—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.0104	0.0268	CbGbCtD
Maprotiline—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.0103	0.0267	CbGbCtD
Maprotiline—CYP1A2—Losartan—type 2 diabetes mellitus	0.00809	0.0209	CbGbCtD
Maprotiline—ABCB1—Glyburide—type 2 diabetes mellitus	0.00774	0.02	CbGbCtD
Maprotiline—ABCB1—Losartan—type 2 diabetes mellitus	0.00708	0.0183	CbGbCtD
Maprotiline—SLC6A2—sympathetic nervous system—type 2 diabetes mellitus	0.00309	0.0875	CbGeAlD
Maprotiline—HTR7—sympathetic nervous system—type 2 diabetes mellitus	0.00298	0.0843	CbGeAlD
Maprotiline—HTR2A—arteriole—type 2 diabetes mellitus	0.00292	0.0825	CbGeAlD
Maprotiline—SLC6A2—autonomic nervous system—type 2 diabetes mellitus	0.00208	0.0588	CbGeAlD
Maprotiline—HTR7—autonomic nervous system—type 2 diabetes mellitus	0.002	0.0567	CbGeAlD
Maprotiline—HTR2A—sympathetic nervous system—type 2 diabetes mellitus	0.00186	0.0526	CbGeAlD
Maprotiline—SLC6A3—nerve—type 2 diabetes mellitus	0.00145	0.041	CbGeAlD
Maprotiline—HTR7—peripheral nervous system—type 2 diabetes mellitus	0.00145	0.0409	CbGeAlD
Maprotiline—HTR2A—autonomic nervous system—type 2 diabetes mellitus	0.00125	0.0353	CbGeAlD
Maprotiline—SLC6A2—nerve—type 2 diabetes mellitus	0.00117	0.0331	CbGeAlD
Maprotiline—HTR2A—hindlimb—type 2 diabetes mellitus	0.00116	0.0327	CbGeAlD
Maprotiline—HTR7—artery—type 2 diabetes mellitus	0.00114	0.0321	CbGeAlD
Maprotiline—HTR7—nerve—type 2 diabetes mellitus	0.00113	0.0319	CbGeAlD
Maprotiline—DRD2—nerve—type 2 diabetes mellitus	0.00107	0.0301	CbGeAlD
Maprotiline—HTR7—endothelium—type 2 diabetes mellitus	0.00096	0.0271	CbGeAlD
Maprotiline—HTR2A—peripheral nervous system—type 2 diabetes mellitus	0.000901	0.0255	CbGeAlD
Maprotiline—HTR2A—artery—type 2 diabetes mellitus	0.000708	0.02	CbGeAlD
Maprotiline—HTR2A—nerve—type 2 diabetes mellitus	0.000703	0.0199	CbGeAlD
Maprotiline—HTR2A—endothelium—type 2 diabetes mellitus	0.000598	0.0169	CbGeAlD
Maprotiline—Sertraline—CYP1A2—type 2 diabetes mellitus	0.000518	0.196	CrCbGaD
Maprotiline—CHRM2—cardiovascular system—type 2 diabetes mellitus	0.000509	0.0144	CbGeAlD
Maprotiline—CHRM1—cardiovascular system—type 2 diabetes mellitus	0.000463	0.0131	CbGeAlD
Maprotiline—DRD2—retina—type 2 diabetes mellitus	0.000441	0.0125	CbGeAlD
Maprotiline—CHRM3—kidney—type 2 diabetes mellitus	0.000406	0.0115	CbGeAlD
Maprotiline—HTR7—cardiovascular system—type 2 diabetes mellitus	0.000395	0.0112	CbGeAlD
Maprotiline—HTR7—kidney—type 2 diabetes mellitus	0.000386	0.0109	CbGeAlD
Maprotiline—CHRM3—adipose tissue—type 2 diabetes mellitus	0.000366	0.0103	CbGeAlD
Maprotiline—Sertraline—CYP3A4—type 2 diabetes mellitus	0.000343	0.13	CrCbGaD
Maprotiline—ORM1—liver—type 2 diabetes mellitus	0.000338	0.00955	CbGeAlD
Maprotiline—Metixene—HTR2C—type 2 diabetes mellitus	0.000294	0.111	CrCbGaD
Maprotiline—HTR2A—retina—type 2 diabetes mellitus	0.000291	0.00823	CbGeAlD
Maprotiline—HRH1—adipose tissue—type 2 diabetes mellitus	0.00026	0.00735	CbGeAlD
Maprotiline—HTR2A—cardiovascular system—type 2 diabetes mellitus	0.000246	0.00696	CbGeAlD
Maprotiline—HTR7—liver—type 2 diabetes mellitus	0.000244	0.00691	CbGeAlD
Maprotiline—HTR2A—kidney—type 2 diabetes mellitus	0.000241	0.00681	CbGeAlD
Maprotiline—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000223	0.00631	CbGeAlD
Maprotiline—CYP2D6—kidney—type 2 diabetes mellitus	0.000219	0.00621	CbGeAlD
Maprotiline—CYP1A2—liver—type 2 diabetes mellitus	0.000195	0.00551	CbGeAlD
Maprotiline—ABCB1—retina—type 2 diabetes mellitus	0.000191	0.00539	CbGeAlD
Maprotiline—ABCB1—nephron tubule—type 2 diabetes mellitus	0.00018	0.00508	CbGeAlD
Maprotiline—Atomoxetine—HTR2C—type 2 diabetes mellitus	0.000173	0.0655	CrCbGaD
Maprotiline—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.000161	0.00456	CbGeAlD
Maprotiline—ABCB1—kidney—type 2 diabetes mellitus	0.000158	0.00446	CbGeAlD
Maprotiline—ABCB1—pancreas—type 2 diabetes mellitus	0.000157	0.00444	CbGeAlD
Maprotiline—ABCB1—cortex of kidney—type 2 diabetes mellitus	0.000154	0.00435	CbGeAlD
Maprotiline—HTR2A—liver—type 2 diabetes mellitus	0.000152	0.00431	CbGeAlD
Maprotiline—Nortriptyline—HTR2C—type 2 diabetes mellitus	0.000151	0.0572	CrCbGaD
Maprotiline—ABCB1—adipose tissue—type 2 diabetes mellitus	0.000142	0.00402	CbGeAlD
Maprotiline—CYP2D6—liver—type 2 diabetes mellitus	0.000139	0.00392	CbGeAlD
Maprotiline—Desipramine—HTR2C—type 2 diabetes mellitus	0.000124	0.0471	CrCbGaD
Maprotiline—Nortriptyline—CYP2E1—type 2 diabetes mellitus	0.00012	0.0454	CrCbGaD
Maprotiline—Nortriptyline—CYP1A2—type 2 diabetes mellitus	0.000114	0.0432	CrCbGaD
Maprotiline—Imipramine—HTR2C—type 2 diabetes mellitus	0.000105	0.0399	CrCbGaD
Maprotiline—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000103	0.000625	CcSEcCtD
Maprotiline—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000103	0.000624	CcSEcCtD
Maprotiline—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000103	0.000624	CcSEcCtD
Maprotiline—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000103	0.000623	CcSEcCtD
Maprotiline—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000103	0.000623	CcSEcCtD
Maprotiline—Agitation—Irbesartan—type 2 diabetes mellitus	0.000102	0.000622	CcSEcCtD
Maprotiline—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000102	0.000622	CcSEcCtD
Maprotiline—Hypertension—Metformin—type 2 diabetes mellitus	0.000102	0.000619	CcSEcCtD
Maprotiline—Urticaria—Glyburide—type 2 diabetes mellitus	0.000102	0.000619	CcSEcCtD
Maprotiline—Nervousness—Losartan—type 2 diabetes mellitus	0.000102	0.000618	CcSEcCtD
Maprotiline—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000102	0.000617	CcSEcCtD
Maprotiline—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000101	0.000616	CcSEcCtD
Maprotiline—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.000101	0.000616	CcSEcCtD
Maprotiline—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	0.000101	0.000614	CcSEcCtD
Maprotiline—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000101	0.000611	CcSEcCtD
Maprotiline—Headache—Pioglitazone—type 2 diabetes mellitus	0.0001	0.000607	CcSEcCtD
Maprotiline—Syncope—Irbesartan—type 2 diabetes mellitus	0.0001	0.000607	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	9.99e-05	0.000606	CcSEcCtD
Maprotiline—Leukopenia—Irbesartan—type 2 diabetes mellitus	9.98e-05	0.000606	CcSEcCtD
Maprotiline—ABCB1—liver—type 2 diabetes mellitus	9.98e-05	0.00282	CbGeAlD
Maprotiline—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	9.95e-05	0.000604	CcSEcCtD
Maprotiline—Fatigue—Gliclazide—type 2 diabetes mellitus	9.94e-05	0.000603	CcSEcCtD
Maprotiline—Nausea—Glipizide—type 2 diabetes mellitus	9.91e-05	0.000601	CcSEcCtD
Maprotiline—Vomiting—Glimepiride—type 2 diabetes mellitus	9.9e-05	0.0006	CcSEcCtD
Maprotiline—Hypotension—Valsartan—type 2 diabetes mellitus	9.9e-05	0.0006	CcSEcCtD
Maprotiline—Vision blurred—Losartan—type 2 diabetes mellitus	9.89e-05	0.0006	CcSEcCtD
Maprotiline—Vomiting—Sitagliptin—type 2 diabetes mellitus	9.86e-05	0.000599	CcSEcCtD
Maprotiline—Desipramine—CYP2E1—type 2 diabetes mellitus	9.86e-05	0.0374	CrCbGaD
Maprotiline—Constipation—Gliclazide—type 2 diabetes mellitus	9.86e-05	0.000598	CcSEcCtD
Maprotiline—Tremor—Losartan—type 2 diabetes mellitus	9.83e-05	0.000597	CcSEcCtD
Maprotiline—Rash—Glimepiride—type 2 diabetes mellitus	9.81e-05	0.000595	CcSEcCtD
Maprotiline—Dermatitis—Glimepiride—type 2 diabetes mellitus	9.8e-05	0.000595	CcSEcCtD
Maprotiline—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	9.8e-05	0.000595	CcSEcCtD
Maprotiline—Rash—Sitagliptin—type 2 diabetes mellitus	9.78e-05	0.000594	CcSEcCtD
Maprotiline—Dermatitis—Sitagliptin—type 2 diabetes mellitus	9.77e-05	0.000593	CcSEcCtD
Maprotiline—Erythema multiforme—Ramipril—type 2 diabetes mellitus	9.77e-05	0.000593	CcSEcCtD
Maprotiline—Headache—Glimepiride—type 2 diabetes mellitus	9.75e-05	0.000592	CcSEcCtD
Maprotiline—Headache—Sitagliptin—type 2 diabetes mellitus	9.72e-05	0.00059	CcSEcCtD
Maprotiline—Agitation—Losartan—type 2 diabetes mellitus	9.64e-05	0.000585	CcSEcCtD
Maprotiline—Oedema—Metformin—type 2 diabetes mellitus	9.64e-05	0.000585	CcSEcCtD
Maprotiline—Tinnitus—Ramipril—type 2 diabetes mellitus	9.64e-05	0.000585	CcSEcCtD
Maprotiline—Hypertension—Irbesartan—type 2 diabetes mellitus	9.63e-05	0.000584	CcSEcCtD
Maprotiline—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	9.61e-05	0.000583	CcSEcCtD
Maprotiline—Flushing—Ramipril—type 2 diabetes mellitus	9.59e-05	0.000582	CcSEcCtD
Maprotiline—Infection—Metformin—type 2 diabetes mellitus	9.58e-05	0.000581	CcSEcCtD
Maprotiline—Insomnia—Valsartan—type 2 diabetes mellitus	9.58e-05	0.000581	CcSEcCtD
Maprotiline—Paraesthesia—Valsartan—type 2 diabetes mellitus	9.51e-05	0.000577	CcSEcCtD
Maprotiline—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	9.5e-05	0.000576	CcSEcCtD
Maprotiline—Shock—Metformin—type 2 diabetes mellitus	9.49e-05	0.000576	CcSEcCtD
Maprotiline—Insomnia—Orlistat—type 2 diabetes mellitus	9.46e-05	0.000574	CcSEcCtD
Maprotiline—Anxiety—Irbesartan—type 2 diabetes mellitus	9.46e-05	0.000574	CcSEcCtD
Maprotiline—Nervous system disorder—Metformin—type 2 diabetes mellitus	9.46e-05	0.000574	CcSEcCtD
Maprotiline—Thrombocytopenia—Metformin—type 2 diabetes mellitus	9.44e-05	0.000573	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	9.43e-05	0.000572	CcSEcCtD
Maprotiline—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	9.43e-05	0.000572	CcSEcCtD
Maprotiline—Somnolence—Valsartan—type 2 diabetes mellitus	9.41e-05	0.000571	CcSEcCtD
Maprotiline—Syncope—Losartan—type 2 diabetes mellitus	9.41e-05	0.000571	CcSEcCtD
Maprotiline—Paraesthesia—Orlistat—type 2 diabetes mellitus	9.4e-05	0.00057	CcSEcCtD
Maprotiline—Leukopenia—Losartan—type 2 diabetes mellitus	9.39e-05	0.00057	CcSEcCtD
Maprotiline—Desipramine—CYP1A2—type 2 diabetes mellitus	9.38e-05	0.0355	CrCbGaD
Maprotiline—Skin disorder—Metformin—type 2 diabetes mellitus	9.37e-05	0.000568	CcSEcCtD
Maprotiline—Hyperhidrosis—Metformin—type 2 diabetes mellitus	9.32e-05	0.000566	CcSEcCtD
Maprotiline—Dyspepsia—Valsartan—type 2 diabetes mellitus	9.32e-05	0.000566	CcSEcCtD
Maprotiline—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	9.32e-05	0.000565	CcSEcCtD
Maprotiline—Dizziness—Bromocriptine—type 2 diabetes mellitus	9.29e-05	0.000563	CcSEcCtD
Maprotiline—Dry mouth—Irbesartan—type 2 diabetes mellitus	9.28e-05	0.000563	CcSEcCtD
Maprotiline—Palpitations—Losartan—type 2 diabetes mellitus	9.27e-05	0.000563	CcSEcCtD
Maprotiline—Nausea—Glimepiride—type 2 diabetes mellitus	9.25e-05	0.000561	CcSEcCtD
Maprotiline—Arrhythmia—Ramipril—type 2 diabetes mellitus	9.23e-05	0.00056	CcSEcCtD
Maprotiline—Loss of consciousness—Losartan—type 2 diabetes mellitus	9.22e-05	0.00056	CcSEcCtD
Maprotiline—Nausea—Sitagliptin—type 2 diabetes mellitus	9.22e-05	0.000559	CcSEcCtD
Maprotiline—Dyspepsia—Orlistat—type 2 diabetes mellitus	9.21e-05	0.000559	CcSEcCtD
Maprotiline—Asthenia—Glyburide—type 2 diabetes mellitus	9.21e-05	0.000559	CcSEcCtD
Maprotiline—Urticaria—Gliclazide—type 2 diabetes mellitus	9.16e-05	0.000556	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	9.14e-05	0.000555	CcSEcCtD
Maprotiline—Alopecia—Ramipril—type 2 diabetes mellitus	9.13e-05	0.000554	CcSEcCtD
Maprotiline—Fatigue—Valsartan—type 2 diabetes mellitus	9.13e-05	0.000554	CcSEcCtD
Maprotiline—Abdominal pain—Gliclazide—type 2 diabetes mellitus	9.11e-05	0.000553	CcSEcCtD
Maprotiline—Body temperature increased—Gliclazide—type 2 diabetes mellitus	9.11e-05	0.000553	CcSEcCtD
Maprotiline—Oedema—Irbesartan—type 2 diabetes mellitus	9.1e-05	0.000552	CcSEcCtD
Maprotiline—Pruritus—Glyburide—type 2 diabetes mellitus	9.08e-05	0.000551	CcSEcCtD
Maprotiline—Constipation—Valsartan—type 2 diabetes mellitus	9.06e-05	0.000549	CcSEcCtD
Maprotiline—Infection—Irbesartan—type 2 diabetes mellitus	9.04e-05	0.000549	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	9.03e-05	0.000548	CcSEcCtD
Maprotiline—Fatigue—Orlistat—type 2 diabetes mellitus	9.02e-05	0.000547	CcSEcCtD
Maprotiline—Hypotension—Metformin—type 2 diabetes mellitus	9.01e-05	0.000547	CcSEcCtD
Maprotiline—Malnutrition—Ramipril—type 2 diabetes mellitus	9e-05	0.000546	CcSEcCtD
Maprotiline—Shock—Irbesartan—type 2 diabetes mellitus	8.95e-05	0.000543	CcSEcCtD
Maprotiline—Vomiting—Bromocriptine—type 2 diabetes mellitus	8.93e-05	0.000542	CcSEcCtD
Maprotiline—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	8.92e-05	0.000542	CcSEcCtD
Maprotiline—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	8.91e-05	0.000541	CcSEcCtD
Maprotiline—Anxiety—Losartan—type 2 diabetes mellitus	8.9e-05	0.00054	CcSEcCtD
Maprotiline—Tachycardia—Irbesartan—type 2 diabetes mellitus	8.88e-05	0.000539	CcSEcCtD
Maprotiline—Rash—Bromocriptine—type 2 diabetes mellitus	8.85e-05	0.000537	CcSEcCtD
Maprotiline—Dermatitis—Bromocriptine—type 2 diabetes mellitus	8.85e-05	0.000537	CcSEcCtD
Maprotiline—Skin disorder—Irbesartan—type 2 diabetes mellitus	8.84e-05	0.000536	CcSEcCtD
Maprotiline—Tension—Ramipril—type 2 diabetes mellitus	8.83e-05	0.000536	CcSEcCtD
Maprotiline—Dysgeusia—Ramipril—type 2 diabetes mellitus	8.81e-05	0.000535	CcSEcCtD
Maprotiline—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	8.8e-05	0.000534	CcSEcCtD
Maprotiline—Headache—Bromocriptine—type 2 diabetes mellitus	8.8e-05	0.000534	CcSEcCtD
Maprotiline—Diarrhoea—Glyburide—type 2 diabetes mellitus	8.78e-05	0.000533	CcSEcCtD
Maprotiline—Nervousness—Ramipril—type 2 diabetes mellitus	8.74e-05	0.00053	CcSEcCtD
Maprotiline—Dry mouth—Losartan—type 2 diabetes mellitus	8.74e-05	0.00053	CcSEcCtD
Maprotiline—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	8.66e-05	0.000525	CcSEcCtD
Maprotiline—Paraesthesia—Metformin—type 2 diabetes mellitus	8.66e-05	0.000525	CcSEcCtD
Maprotiline—Confusional state—Losartan—type 2 diabetes mellitus	8.64e-05	0.000524	CcSEcCtD
Maprotiline—Atomoxetine—CYP3A4—type 2 diabetes mellitus	8.64e-05	0.0327	CrCbGaD
Maprotiline—Feeling abnormal—Orlistat—type 2 diabetes mellitus	8.62e-05	0.000523	CcSEcCtD
Maprotiline—Somnolence—Metformin—type 2 diabetes mellitus	8.57e-05	0.00052	CcSEcCtD
Maprotiline—Oedema—Losartan—type 2 diabetes mellitus	8.56e-05	0.00052	CcSEcCtD
Maprotiline—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	8.56e-05	0.000519	CcSEcCtD
Maprotiline—Infection—Losartan—type 2 diabetes mellitus	8.51e-05	0.000516	CcSEcCtD
Maprotiline—Hypotension—Irbesartan—type 2 diabetes mellitus	8.5e-05	0.000516	CcSEcCtD
Maprotiline—Dyspepsia—Metformin—type 2 diabetes mellitus	8.49e-05	0.000515	CcSEcCtD
Maprotiline—Tremor—Ramipril—type 2 diabetes mellitus	8.43e-05	0.000512	CcSEcCtD
Maprotiline—Shock—Losartan—type 2 diabetes mellitus	8.43e-05	0.000511	CcSEcCtD
Maprotiline—Urticaria—Valsartan—type 2 diabetes mellitus	8.41e-05	0.00051	CcSEcCtD
Maprotiline—Nervous system disorder—Losartan—type 2 diabetes mellitus	8.4e-05	0.00051	CcSEcCtD
Maprotiline—Thrombocytopenia—Losartan—type 2 diabetes mellitus	8.39e-05	0.000509	CcSEcCtD
Maprotiline—Abdominal pain—Valsartan—type 2 diabetes mellitus	8.37e-05	0.000508	CcSEcCtD
Maprotiline—Imipramine—CYP2E1—type 2 diabetes mellitus	8.36e-05	0.0317	CrCbGaD
Maprotiline—Tachycardia—Losartan—type 2 diabetes mellitus	8.36e-05	0.000507	CcSEcCtD
Maprotiline—Nausea—Bromocriptine—type 2 diabetes mellitus	8.34e-05	0.000506	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	8.33e-05	0.000505	CcSEcCtD
Maprotiline—Fatigue—Metformin—type 2 diabetes mellitus	8.31e-05	0.000504	CcSEcCtD
Maprotiline—Urticaria—Orlistat—type 2 diabetes mellitus	8.31e-05	0.000504	CcSEcCtD
Maprotiline—Hyperhidrosis—Losartan—type 2 diabetes mellitus	8.28e-05	0.000502	CcSEcCtD
Maprotiline—Body temperature increased—Orlistat—type 2 diabetes mellitus	8.27e-05	0.000502	CcSEcCtD
Maprotiline—Abdominal pain—Orlistat—type 2 diabetes mellitus	8.27e-05	0.000502	CcSEcCtD
Maprotiline—Asthenia—Gliclazide—type 2 diabetes mellitus	8.27e-05	0.000502	CcSEcCtD
Maprotiline—Agitation—Ramipril—type 2 diabetes mellitus	8.27e-05	0.000502	CcSEcCtD
Maprotiline—Constipation—Metformin—type 2 diabetes mellitus	8.25e-05	0.0005	CcSEcCtD
Maprotiline—Paraesthesia—Irbesartan—type 2 diabetes mellitus	8.17e-05	0.000496	CcSEcCtD
Maprotiline—Vomiting—Glyburide—type 2 diabetes mellitus	8.16e-05	0.000495	CcSEcCtD
Maprotiline—Pruritus—Gliclazide—type 2 diabetes mellitus	8.15e-05	0.000495	CcSEcCtD
Maprotiline—Rash—Glyburide—type 2 diabetes mellitus	8.09e-05	0.000491	CcSEcCtD
Maprotiline—Somnolence—Irbesartan—type 2 diabetes mellitus	8.09e-05	0.000491	CcSEcCtD
Maprotiline—Dermatitis—Glyburide—type 2 diabetes mellitus	8.09e-05	0.000491	CcSEcCtD
Maprotiline—Syncope—Ramipril—type 2 diabetes mellitus	8.07e-05	0.00049	CcSEcCtD
Maprotiline—Leukopenia—Ramipril—type 2 diabetes mellitus	8.05e-05	0.000489	CcSEcCtD
Maprotiline—Headache—Glyburide—type 2 diabetes mellitus	8.04e-05	0.000488	CcSEcCtD
Maprotiline—Dyspepsia—Irbesartan—type 2 diabetes mellitus	8.01e-05	0.000486	CcSEcCtD
Maprotiline—Hypotension—Losartan—type 2 diabetes mellitus	8e-05	0.000486	CcSEcCtD
Maprotiline—Imipramine—CYP1A2—type 2 diabetes mellitus	7.96e-05	0.0301	CrCbGaD
Maprotiline—Palpitations—Ramipril—type 2 diabetes mellitus	7.95e-05	0.000483	CcSEcCtD
Maprotiline—Feeling abnormal—Metformin—type 2 diabetes mellitus	7.95e-05	0.000482	CcSEcCtD
Maprotiline—Loss of consciousness—Ramipril—type 2 diabetes mellitus	7.91e-05	0.00048	CcSEcCtD
Maprotiline—Diarrhoea—Gliclazide—type 2 diabetes mellitus	7.89e-05	0.000479	CcSEcCtD
Maprotiline—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	7.89e-05	0.000478	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	7.86e-05	0.000477	CcSEcCtD
Maprotiline—Fatigue—Irbesartan—type 2 diabetes mellitus	7.85e-05	0.000476	CcSEcCtD
Maprotiline—Convulsion—Ramipril—type 2 diabetes mellitus	7.8e-05	0.000473	CcSEcCtD
Maprotiline—Constipation—Irbesartan—type 2 diabetes mellitus	7.78e-05	0.000472	CcSEcCtD
Maprotiline—Insomnia—Losartan—type 2 diabetes mellitus	7.75e-05	0.00047	CcSEcCtD
Maprotiline—Paraesthesia—Losartan—type 2 diabetes mellitus	7.69e-05	0.000467	CcSEcCtD
Maprotiline—Urticaria—Metformin—type 2 diabetes mellitus	7.66e-05	0.000465	CcSEcCtD
Maprotiline—Anxiety—Ramipril—type 2 diabetes mellitus	7.63e-05	0.000463	CcSEcCtD
Maprotiline—Nausea—Glyburide—type 2 diabetes mellitus	7.62e-05	0.000463	CcSEcCtD
Maprotiline—Abdominal pain—Metformin—type 2 diabetes mellitus	7.62e-05	0.000463	CcSEcCtD
Maprotiline—Dizziness—Gliclazide—type 2 diabetes mellitus	7.62e-05	0.000462	CcSEcCtD
Maprotiline—Somnolence—Losartan—type 2 diabetes mellitus	7.61e-05	0.000462	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	7.61e-05	0.000462	CcSEcCtD
Maprotiline—Asthenia—Valsartan—type 2 diabetes mellitus	7.6e-05	0.000461	CcSEcCtD
Maprotiline—Nortriptyline—CYP3A4—type 2 diabetes mellitus	7.54e-05	0.0286	CrCbGaD
Maprotiline—Dyspepsia—Losartan—type 2 diabetes mellitus	7.54e-05	0.000457	CcSEcCtD
Maprotiline—Asthenia—Orlistat—type 2 diabetes mellitus	7.51e-05	0.000456	CcSEcCtD
Maprotiline—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	7.5e-05	0.000455	CcSEcCtD
Maprotiline—Pruritus—Valsartan—type 2 diabetes mellitus	7.49e-05	0.000455	CcSEcCtD
Maprotiline—Dry mouth—Ramipril—type 2 diabetes mellitus	7.49e-05	0.000455	CcSEcCtD
Maprotiline—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	7.44e-05	0.000452	CcSEcCtD
Maprotiline—Confusional state—Ramipril—type 2 diabetes mellitus	7.4e-05	0.000449	CcSEcCtD
Maprotiline—Pruritus—Orlistat—type 2 diabetes mellitus	7.4e-05	0.000449	CcSEcCtD
Maprotiline—Fatigue—Losartan—type 2 diabetes mellitus	7.38e-05	0.000448	CcSEcCtD
Maprotiline—Oedema—Ramipril—type 2 diabetes mellitus	7.34e-05	0.000446	CcSEcCtD
Maprotiline—Vomiting—Gliclazide—type 2 diabetes mellitus	7.33e-05	0.000445	CcSEcCtD
Maprotiline—Constipation—Losartan—type 2 diabetes mellitus	7.32e-05	0.000444	CcSEcCtD
Maprotiline—Rash—Gliclazide—type 2 diabetes mellitus	7.27e-05	0.000441	CcSEcCtD
Maprotiline—Dermatitis—Gliclazide—type 2 diabetes mellitus	7.26e-05	0.000441	CcSEcCtD
Maprotiline—Diarrhoea—Valsartan—type 2 diabetes mellitus	7.25e-05	0.00044	CcSEcCtD
Maprotiline—Urticaria—Irbesartan—type 2 diabetes mellitus	7.23e-05	0.000439	CcSEcCtD
Maprotiline—Shock—Ramipril—type 2 diabetes mellitus	7.23e-05	0.000438	CcSEcCtD
Maprotiline—Headache—Gliclazide—type 2 diabetes mellitus	7.22e-05	0.000438	CcSEcCtD
Maprotiline—Nervous system disorder—Ramipril—type 2 diabetes mellitus	7.2e-05	0.000437	CcSEcCtD
Maprotiline—Body temperature increased—Irbesartan—type 2 diabetes mellitus	7.19e-05	0.000437	CcSEcCtD
Maprotiline—Abdominal pain—Irbesartan—type 2 diabetes mellitus	7.19e-05	0.000437	CcSEcCtD
Maprotiline—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	7.19e-05	0.000436	CcSEcCtD
Maprotiline—Tachycardia—Ramipril—type 2 diabetes mellitus	7.17e-05	0.000435	CcSEcCtD
Maprotiline—Diarrhoea—Orlistat—type 2 diabetes mellitus	7.16e-05	0.000434	CcSEcCtD
Maprotiline—Skin disorder—Ramipril—type 2 diabetes mellitus	7.13e-05	0.000433	CcSEcCtD
Maprotiline—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	7.1e-05	0.000431	CcSEcCtD
Maprotiline—Feeling abnormal—Losartan—type 2 diabetes mellitus	7.06e-05	0.000428	CcSEcCtD
Maprotiline—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	7e-05	0.000425	CcSEcCtD
Maprotiline—Dizziness—Valsartan—type 2 diabetes mellitus	7e-05	0.000425	CcSEcCtD
Maprotiline—Dizziness—Orlistat—type 2 diabetes mellitus	6.92e-05	0.00042	CcSEcCtD
Maprotiline—Asthenia—Metformin—type 2 diabetes mellitus	6.92e-05	0.00042	CcSEcCtD
Maprotiline—Hypotension—Ramipril—type 2 diabetes mellitus	6.86e-05	0.000416	CcSEcCtD
Maprotiline—Nausea—Gliclazide—type 2 diabetes mellitus	6.85e-05	0.000415	CcSEcCtD
Maprotiline—Pruritus—Metformin—type 2 diabetes mellitus	6.82e-05	0.000414	CcSEcCtD
Maprotiline—Urticaria—Losartan—type 2 diabetes mellitus	6.8e-05	0.000413	CcSEcCtD
Maprotiline—Abdominal pain—Losartan—type 2 diabetes mellitus	6.77e-05	0.000411	CcSEcCtD
Maprotiline—Body temperature increased—Losartan—type 2 diabetes mellitus	6.77e-05	0.000411	CcSEcCtD
Maprotiline—Vomiting—Valsartan—type 2 diabetes mellitus	6.73e-05	0.000409	CcSEcCtD
Maprotiline—Rash—Valsartan—type 2 diabetes mellitus	6.68e-05	0.000405	CcSEcCtD
Maprotiline—Dermatitis—Valsartan—type 2 diabetes mellitus	6.67e-05	0.000405	CcSEcCtD
Maprotiline—Vomiting—Orlistat—type 2 diabetes mellitus	6.65e-05	0.000404	CcSEcCtD
Maprotiline—Insomnia—Ramipril—type 2 diabetes mellitus	6.64e-05	0.000403	CcSEcCtD
Maprotiline—Headache—Valsartan—type 2 diabetes mellitus	6.63e-05	0.000403	CcSEcCtD
Maprotiline—Diarrhoea—Metformin—type 2 diabetes mellitus	6.6e-05	0.0004	CcSEcCtD
Maprotiline—Rash—Orlistat—type 2 diabetes mellitus	6.6e-05	0.0004	CcSEcCtD
Maprotiline—Paraesthesia—Ramipril—type 2 diabetes mellitus	6.59e-05	0.0004	CcSEcCtD
Maprotiline—Dermatitis—Orlistat—type 2 diabetes mellitus	6.59e-05	0.0004	CcSEcCtD
Maprotiline—Nortriptyline—ALB—type 2 diabetes mellitus	6.58e-05	0.0249	CrCbGaD
Maprotiline—Headache—Orlistat—type 2 diabetes mellitus	6.56e-05	0.000398	CcSEcCtD
Maprotiline—Asthenia—Irbesartan—type 2 diabetes mellitus	6.53e-05	0.000396	CcSEcCtD
Maprotiline—Somnolence—Ramipril—type 2 diabetes mellitus	6.53e-05	0.000396	CcSEcCtD
Maprotiline—Dyspepsia—Ramipril—type 2 diabetes mellitus	6.46e-05	0.000392	CcSEcCtD
Maprotiline—Pruritus—Irbesartan—type 2 diabetes mellitus	6.44e-05	0.000391	CcSEcCtD
Maprotiline—Dizziness—Metformin—type 2 diabetes mellitus	6.38e-05	0.000387	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	6.34e-05	0.000385	CcSEcCtD
Maprotiline—Fatigue—Ramipril—type 2 diabetes mellitus	6.33e-05	0.000384	CcSEcCtD
Maprotiline—Nausea—Valsartan—type 2 diabetes mellitus	6.29e-05	0.000382	CcSEcCtD
Maprotiline—Constipation—Ramipril—type 2 diabetes mellitus	6.28e-05	0.000381	CcSEcCtD
Maprotiline—Diarrhoea—Irbesartan—type 2 diabetes mellitus	6.23e-05	0.000378	CcSEcCtD
Maprotiline—Nausea—Orlistat—type 2 diabetes mellitus	6.22e-05	0.000377	CcSEcCtD
Maprotiline—Desipramine—CYP3A4—type 2 diabetes mellitus	6.21e-05	0.0235	CrCbGaD
Maprotiline—Asthenia—Losartan—type 2 diabetes mellitus	6.14e-05	0.000373	CcSEcCtD
Maprotiline—Vomiting—Metformin—type 2 diabetes mellitus	6.13e-05	0.000372	CcSEcCtD
Maprotiline—Rash—Metformin—type 2 diabetes mellitus	6.08e-05	0.000369	CcSEcCtD
Maprotiline—Dermatitis—Metformin—type 2 diabetes mellitus	6.07e-05	0.000369	CcSEcCtD
Maprotiline—Pruritus—Losartan—type 2 diabetes mellitus	6.06e-05	0.000368	CcSEcCtD
Maprotiline—Feeling abnormal—Ramipril—type 2 diabetes mellitus	6.05e-05	0.000367	CcSEcCtD
Maprotiline—Headache—Metformin—type 2 diabetes mellitus	6.04e-05	0.000367	CcSEcCtD
Maprotiline—Dizziness—Irbesartan—type 2 diabetes mellitus	6.02e-05	0.000365	CcSEcCtD
Maprotiline—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	6.01e-05	0.000364	CcSEcCtD
Maprotiline—Diarrhoea—Losartan—type 2 diabetes mellitus	5.86e-05	0.000356	CcSEcCtD
Maprotiline—Urticaria—Ramipril—type 2 diabetes mellitus	5.83e-05	0.000354	CcSEcCtD
Maprotiline—Abdominal pain—Ramipril—type 2 diabetes mellitus	5.81e-05	0.000352	CcSEcCtD
Maprotiline—Body temperature increased—Ramipril—type 2 diabetes mellitus	5.81e-05	0.000352	CcSEcCtD
Maprotiline—Vomiting—Irbesartan—type 2 diabetes mellitus	5.79e-05	0.000351	CcSEcCtD
Maprotiline—Rash—Irbesartan—type 2 diabetes mellitus	5.74e-05	0.000348	CcSEcCtD
Maprotiline—Dermatitis—Irbesartan—type 2 diabetes mellitus	5.73e-05	0.000348	CcSEcCtD
Maprotiline—Nausea—Metformin—type 2 diabetes mellitus	5.73e-05	0.000348	CcSEcCtD
Maprotiline—Headache—Irbesartan—type 2 diabetes mellitus	5.7e-05	0.000346	CcSEcCtD
Maprotiline—Dizziness—Losartan—type 2 diabetes mellitus	5.66e-05	0.000344	CcSEcCtD
Maprotiline—Vomiting—Losartan—type 2 diabetes mellitus	5.45e-05	0.00033	CcSEcCtD
Maprotiline—Nausea—Irbesartan—type 2 diabetes mellitus	5.41e-05	0.000328	CcSEcCtD
Maprotiline—Rash—Losartan—type 2 diabetes mellitus	5.4e-05	0.000328	CcSEcCtD
Maprotiline—Dermatitis—Losartan—type 2 diabetes mellitus	5.4e-05	0.000327	CcSEcCtD
Maprotiline—Headache—Losartan—type 2 diabetes mellitus	5.37e-05	0.000326	CcSEcCtD
Maprotiline—Asthenia—Ramipril—type 2 diabetes mellitus	5.27e-05	0.00032	CcSEcCtD
Maprotiline—Imipramine—CYP3A4—type 2 diabetes mellitus	5.27e-05	0.02	CrCbGaD
Maprotiline—Pruritus—Ramipril—type 2 diabetes mellitus	5.2e-05	0.000315	CcSEcCtD
Maprotiline—Nausea—Losartan—type 2 diabetes mellitus	5.09e-05	0.000309	CcSEcCtD
Maprotiline—Diarrhoea—Ramipril—type 2 diabetes mellitus	5.02e-05	0.000305	CcSEcCtD
Maprotiline—Dizziness—Ramipril—type 2 diabetes mellitus	4.86e-05	0.000295	CcSEcCtD
Maprotiline—Vomiting—Ramipril—type 2 diabetes mellitus	4.67e-05	0.000283	CcSEcCtD
Maprotiline—Rash—Ramipril—type 2 diabetes mellitus	4.63e-05	0.000281	CcSEcCtD
Maprotiline—Dermatitis—Ramipril—type 2 diabetes mellitus	4.63e-05	0.000281	CcSEcCtD
Maprotiline—Headache—Ramipril—type 2 diabetes mellitus	4.6e-05	0.000279	CcSEcCtD
Maprotiline—Nausea—Ramipril—type 2 diabetes mellitus	4.36e-05	0.000265	CcSEcCtD
Maprotiline—CHRM3—Metabolism—ALB—type 2 diabetes mellitus	2.97e-06	3.41e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.96e-06	3.4e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	2.96e-06	3.39e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	2.96e-06	3.39e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	2.92e-06	3.35e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	2.92e-06	3.35e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	2.92e-06	3.35e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	2.92e-06	3.35e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.91e-06	3.34e-05	CbGpPWpGaD
Maprotiline—CHRM5—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.9e-06	3.33e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.9e-06	3.33e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.89e-06	3.32e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.87e-06	3.3e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	2.87e-06	3.29e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.85e-06	3.27e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.85e-06	3.27e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.85e-06	3.27e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PIK3R1—type 2 diabetes mellitus	2.84e-06	3.26e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—NOS3—type 2 diabetes mellitus	2.84e-06	3.26e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.84e-06	3.26e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.84e-06	3.25e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	2.83e-06	3.25e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.83e-06	3.24e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	2.81e-06	3.22e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.81e-06	3.22e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.8e-06	3.21e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	2.8e-06	3.21e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—INS—type 2 diabetes mellitus	2.78e-06	3.19e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—SRC—type 2 diabetes mellitus	2.77e-06	3.18e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.76e-06	3.17e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.76e-06	3.17e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	2.76e-06	3.16e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.75e-06	3.15e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—INS—type 2 diabetes mellitus	2.73e-06	3.13e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.73e-06	3.13e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	2.73e-06	3.13e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—INS—type 2 diabetes mellitus	2.73e-06	3.13e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—INS—type 2 diabetes mellitus	2.72e-06	3.12e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.72e-06	3.12e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—INS—type 2 diabetes mellitus	2.71e-06	3.11e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	2.71e-06	3.1e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.7e-06	3.09e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	2.69e-06	3.09e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.69e-06	3.08e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.69e-06	3.08e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.69e-06	3.08e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.68e-06	3.08e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—INS—type 2 diabetes mellitus	2.68e-06	3.08e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.68e-06	3.08e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.67e-06	3.07e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.67e-06	3.07e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.67e-06	3.06e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	2.65e-06	3.04e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.64e-06	3.03e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.64e-06	3.03e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.64e-06	3.03e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	2.64e-06	3.03e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.64e-06	3.02e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.64e-06	3.02e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.63e-06	3.02e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.63e-06	3.02e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.63e-06	3.02e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.63e-06	3.01e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.62e-06	3.01e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.62e-06	3.01e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.62e-06	3e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.62e-06	3e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—SRC—type 2 diabetes mellitus	2.61e-06	3e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.61e-06	2.99e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PTGS2—type 2 diabetes mellitus	2.6e-06	2.98e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—RELA—type 2 diabetes mellitus	2.6e-06	2.98e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.59e-06	2.98e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.59e-06	2.97e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	2.58e-06	2.96e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.58e-06	2.96e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	2.57e-06	2.95e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.55e-06	2.93e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.55e-06	2.92e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	2.54e-06	2.91e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	2.54e-06	2.91e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	2.52e-06	2.89e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.52e-06	2.89e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.51e-06	2.88e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	2.51e-06	2.87e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.5e-06	2.87e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—SRC—type 2 diabetes mellitus	2.5e-06	2.87e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.5e-06	2.86e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.49e-06	2.85e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.47e-06	2.84e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	2.47e-06	2.84e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.46e-06	2.83e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	2.46e-06	2.82e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.44e-06	2.8e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	2.44e-06	2.79e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.44e-06	2.79e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.44e-06	2.79e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.43e-06	2.78e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	2.41e-06	2.77e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	2.41e-06	2.76e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	2.4e-06	2.75e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.4e-06	2.75e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.4e-06	2.75e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.39e-06	2.74e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.39e-06	2.74e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	2.39e-06	2.74e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.38e-06	2.73e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.38e-06	2.73e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	2.38e-06	2.73e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.38e-06	2.73e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.38e-06	2.73e-05	CbGpPWpGaD
Maprotiline—HTR2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.36e-06	2.71e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.35e-06	2.7e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.35e-06	2.7e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.34e-06	2.69e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.34e-06	2.68e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	2.33e-06	2.68e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.33e-06	2.67e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	2.31e-06	2.65e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—RELA—type 2 diabetes mellitus	2.29e-06	2.63e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	2.29e-06	2.63e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.29e-06	2.63e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	2.28e-06	2.61e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	2.27e-06	2.6e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—RELA—type 2 diabetes mellitus	2.26e-06	2.59e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—RELA—type 2 diabetes mellitus	2.25e-06	2.58e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	2.24e-06	2.57e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	2.24e-06	2.57e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	2.24e-06	2.57e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.24e-06	2.57e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—RELA—type 2 diabetes mellitus	2.24e-06	2.57e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	2.24e-06	2.56e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—RELA—type 2 diabetes mellitus	2.21e-06	2.54e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.21e-06	2.54e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.19e-06	2.52e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.19e-06	2.51e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	2.18e-06	2.5e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	2.15e-06	2.47e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.15e-06	2.46e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	2.1e-06	2.4e-05	CbGpPWpGaD
Maprotiline—DRD2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.09e-06	2.39e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.07e-06	2.37e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	2.06e-06	2.37e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—INS—type 2 diabetes mellitus	2.06e-06	2.36e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.05e-06	2.36e-05	CbGpPWpGaD
Maprotiline—HTR2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.05e-06	2.36e-05	CbGpPWpGaD
Maprotiline—HRH1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.05e-06	2.35e-05	CbGpPWpGaD
Maprotiline—CHRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.04e-06	2.34e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—SRC—type 2 diabetes mellitus	2.04e-06	2.34e-05	CbGpPWpGaD
Maprotiline—CHRM3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.04e-06	2.34e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.03e-06	2.33e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.03e-06	2.33e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	2.02e-06	2.32e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.02e-06	2.32e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.02e-06	2.32e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.02e-06	2.31e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.02e-06	2.31e-05	CbGpPWpGaD
Maprotiline—CHRM2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.02e-06	2.31e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.01e-06	2.31e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—IL6—type 2 diabetes mellitus	2e-06	2.3e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	2e-06	2.29e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.99e-06	2.28e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.98e-06	2.28e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	1.97e-06	2.27e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	1.96e-06	2.25e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.95e-06	2.24e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	1.94e-06	2.22e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.93e-06	2.22e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	1.93e-06	2.21e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.92e-06	2.21e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	1.92e-06	2.2e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.92e-06	2.2e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.91e-06	2.19e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.91e-06	2.19e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.9e-06	2.18e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	1.9e-06	2.18e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.9e-06	2.18e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.89e-06	2.17e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.89e-06	2.17e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.89e-06	2.17e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.89e-06	2.16e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	1.88e-06	2.16e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.87e-06	2.14e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—IL6—type 2 diabetes mellitus	1.86e-06	2.14e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.86e-06	2.14e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.86e-06	2.13e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.85e-06	2.13e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.85e-06	2.12e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.83e-06	2.1e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.82e-06	2.09e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.8e-06	2.07e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	1.8e-06	2.07e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—SRC—type 2 diabetes mellitus	1.8e-06	2.07e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.79e-06	2.05e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	1.78e-06	2.04e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.77e-06	2.03e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.77e-06	2.03e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.76e-06	2.02e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—IL6—type 2 diabetes mellitus	1.76e-06	2.02e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—SRC—type 2 diabetes mellitus	1.76e-06	2.02e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.75e-06	2.01e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—SRC—type 2 diabetes mellitus	1.74e-06	2e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.73e-06	1.98e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.72e-06	1.98e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.72e-06	1.97e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.72e-06	1.97e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.71e-06	1.96e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	1.7e-06	1.95e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	1.7e-06	1.95e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.69e-06	1.94e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—IL6—type 2 diabetes mellitus	1.69e-06	1.93e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	1.67e-06	1.92e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	1.65e-06	1.89e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	1.64e-06	1.88e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.62e-06	1.86e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.61e-06	1.85e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.58e-06	1.82e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.58e-06	1.81e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.58e-06	1.81e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.58e-06	1.81e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.57e-06	1.8e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.56e-06	1.78e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.56e-06	1.78e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	1.55e-06	1.78e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.55e-06	1.78e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.55e-06	1.78e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.55e-06	1.77e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.54e-06	1.77e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.53e-06	1.75e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	1.5e-06	1.73e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	1.44e-06	1.65e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	1.44e-06	1.65e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IL6—type 2 diabetes mellitus	1.37e-06	1.58e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	1.32e-06	1.51e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—AKT1—type 2 diabetes mellitus	1.31e-06	1.5e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.27e-06	1.45e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IL6—type 2 diabetes mellitus	1.21e-06	1.39e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.19e-06	1.37e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.19e-06	1.37e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.19e-06	1.36e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IL6—type 2 diabetes mellitus	1.18e-06	1.36e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IL6—type 2 diabetes mellitus	1.17e-06	1.34e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.12e-06	1.28e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.1e-06	1.26e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.1e-06	1.26e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.1e-06	1.26e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.09e-06	1.25e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.08e-06	1.24e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	8.29e-07	9.51e-06	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	7.81e-07	8.96e-06	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	6.62e-07	7.59e-06	CbGpPWpGaD
